Clinical Trial Update: An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

This Phase 3 extension study evaluating casimersen or golodirsen in Duchenne Muscular Dystrophy has been terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AMONDYS 45 (Casimersen)
• VYONDYS 53 (golodirsen)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: TERMINATED | Results posted: 2024-09-19